Back to the future: Host-targeted chemotherapeutics for drug-resistant TB

Future Microbiology

Volumn 7, Issue 4, 2012, Pages 431-435

  Napier, Ruth J ^a   Shinnick, Thomas M ^b   Kalman, Daniel ^c  

^a EMORY UNIVERSITY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NONE

Author keywords

Abl tyrosine kinase; antibiotic resistance; drug resistance; Gleevec; imatinib; MDR TB; tuberculosis; XDR TB

Indexed keywords

AMIKACIN; BCG VACCINE; CAPREOMYCIN; ETHAMBUTOL; IMATINIB; ISONIAZID; KANAMYCIN; PENICILLIN G; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

AVIAN SARCOMA; BACTERIAL MUTATION; CELL DIVISION; CHLAMYDIA; CHOLERA; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; COXSACKIE VIRUS; DIARRHEAGENIC ESCHERICHIA COLI; FILOVIRUS; GUINEA PIG; HEALTH CARE ACCESS; HELICOBACTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; IN VIVO STUDY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PANDEMIC; PHILADELPHIA 1 CHROMOSOME; PLAGUE; POLYOMA VIRUS; PRIORITY JOURNAL; PSEUDOMONAS; ROUS SARCOMA ONCOVIRUS; SHIGELLA; WEST NILE FLAVIVIRUS; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84858962483     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.19     Document Type: Note

References (56)

1. Osler W, McCrae T. Modern Medicine. (Vol. 3). Osler W (Ed.). Lea Brothers and Co., NY, USA (1907).
2. Koch R. Classics in infectious diseases. The etiology of tuberculosis: Robert Koch. Berlin, Germany 1882. Rev. Infect. Dis. 4(6), 1270-1274 (1982).
3. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. 1944. Clin. Orthop. Relat. Res. (437), 3-6 (2005).
4. Feldman WH, Hinshaw HC, Mann FC. Studies in streptomycin in tuberculosis: the action of streptomycin in experimental tuberculosis. Trans. Annu. Meet. Natl Tuberc. Assoc. 42, 64 (1947).
5. Pfuetze KH, Pyle MM, Hinshaw HC, Feldman WH. The first clinical trial of streptomycin in human tuberculosis. Am. Rev. Tuberc. 71(5), 752-754 (1955).
6. Harris WH. Tuberculosis. William N, Garary S (Eds). Brown and Company, MA, USA (1996).
7. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 54(4), 579-581 (2012).
8. American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recom. Rep. 52(RR-11), 1-77 (2003).
9. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 167(11), 1472-1477 (2003).
10. CDC. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide 2000-2004. MMWR Morb. Mortal. Wkly Rep. 55(11), 301-305 (2006).
11. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 375(9731), 2100-2109 (2010).
12. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271(9), 698-702 (1994).
13. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect. Dis. 11(8), 633-640 (2011).
14. Kupferschmidt K. Infectious disease. Taking a new shot at a TB vaccine. Science 334(6062), 1488-1490 (2011).
15. Balmain A. Cancer genetics: from Boveri and Mendel to microarrays. Nat. Rev. Cancer 1(1), 77-82 (2001).
16. Rous P. A transmissible avian neoplasm. (Sarcoma of the common fowl.). J. Exp. Med. 12(5), 696-705 (1910).
17. Martin GS. Rous sarcoma virus: a function required for the maintenance of the transformed state. Nature 227(5262), 1021-1023 (1970).
18. Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260(5547), 170-173 (1976).
19. Levinson AD, Oppermann H, Levintow L, Varmus HE, Bishop JM. Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein. Cell 15(2), 561-572 (1978).
20. Collett MS, Erikson RL. Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl Acad. Sci. USA 75(4), 2021-2024 (1978).
21. Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297(5866), 474-478 (1982).
22. Koretzky GA. The legacy of the Philadelphia chromosome. J. Clin. Invest. 117(8), 2030-2032 (2007).
23. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 142, 1497 (1960).
24. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405), 290-293 (1973).
25. de Klein A, van Kessel AG, Grosveld G et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300(5894), 765-767 (1982).
26. Goff SP, Gilboa E, Witte ON, Baltimore D. Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell 22(3), 777-785 (1980).
27. Swimm A, Bommarius B, Li Y et al. Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals. Mol. Biol. Cell 15(8), 3520-3529 (2004).
28. Pielage JF, Powell KR, Kalman D, Engel JN. RNAi screen reveals an Abl kinase-dependent host cell pathway involved in Pseudomonas aeruginosa internalization. PLoS Pathog. 4(3), E1000031 (2008).
29. Ly KT, Casanova JE. Abelson tyrosine kinase facilitates Salmonella enterica serovar Typhimurium entry into epithelial cells. Infect. Immun. 77(1), 60-69 (2009).
30. Burton EA, Plattner R, Pendergast AM. Abl tyrosine kinases are required for infection by Shigella flexneri. EMBO J. 22(20), 5471-5479 (2003).
31. Tammer I, Brandt S, Hartig R, König W, Backert S. Activation of Abl by Helicobacter pylori: a novel kinase for CagA and crucial mediator of host cell scattering. Gastroenterology 132(4), 1309-1319 (2007).
32. Elwell CA, Ceesay A, Kim JH, Kalman D, Engel JN. RNA interference screen identifies Abl kinase and PDGFR signaling in Chlamydia trachomatis entry. PLoS Pathog. 4(3), E1000021 (2008).
33. Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124(1), 119-131 (2006).
34. Hirsch AJ, Medigeshi GR, Meyers HL et al. The Src family kinase c-Yes is required for maturation of West Nile virus particles. J. Virol. 79(18), 11943-11951 (2005).
35. Prakash O, Swamy OR, Peng X et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 105(10), 3987-3994 (2005).
36. Reeves PM, Bommarius B, Lebeis S et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 11(7), 731-739 (2005).
37. Swimm AI, Bornmann W, Jiang M, Imperiale MJ, Lukacher AE, Kalman D. Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus. J. Virol. 84(9), 4243-4251 (2010).
38. García M. Productive replication of ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci. Transl. Med. (2012) (In Press).
39. Napier RJ, Rafi W, Cheruvu M et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10(5), 475-485 (2011).
40. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-Abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344(14), 1031-1037 (2001).
41. Reeves PM, Smith SK, Olson VA et al. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and Src family tyrosine kinases. J. Virol. 85(1), 21-31 (2011).
42. Bolton AE, Peng B, Hubert M et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother. Pharmacol. 53(2), 102-106 (2004).
43. Kerkelä R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12(8), 908-916 (2006).
44. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-Abl inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma 49(4), 615-619 (2008).
45. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289(5486), 1938-1942 (2000).
46. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4(2), 75-85 (2003).
47. Jayaswal S, Kamal MA, Dua R et al. Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog. 6(4), E1000839 (2010).
48. Kuijl C, Savage ND, Marsman M et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 450(7170), 725-730 (2007).
49. Kumar D, Nath L, Kamal MA et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 140(5), 731-743 (2010).
50. Pedral-Sampaio DB, Netto EM, Brites C et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz. J. Infect. Dis. 7(4), 245-252 (2003).
51. WHO. 2011/2012 Tuberculosis Global Facts. www.who.int/tb/publications/ 2011/factsheet-tb-2011.pdf
52. Flemming A. Penicillin Nobel Lecture (1945). www.nobelprize.org/nobel- prizes/medicine/laureates/1945/fleming-lecture.html
53. WHO. Global Tuberculosis Control (2011). www.who.int/tb/publications/ global-report/2011/gtbr11-full.pdf
54. WHO. TB: A Global Emergency. http://whqlibdoc.who.int/hq/1994/WHO-TB-94. 177.pdf
55. WHO. Anti-Tuberculosis Drug Resistance in the World, Report No. 4 (2008). www.who.int/tb/publications/2008/drs-report4-26feb08.pdf
56. Stop TB Partnership, WHO. The Global Plan to Stop TB 2006-2015 (2006). www.stoptb.org/global/plan/default.asp